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AVRT ablationIn light of recent reports showing high incidence of silent cerebral infarcts and organized atrial arrhythmias
following radiofrequency (RF) atrial ﬁbrillation (AF) ablation, a review of its safety aspects is timely. Serious
complications do occur during supraventricular tachycardia (SVT) ablations and knowledge of their incidence
is important when deciding whether to proceedwith ablation. Evidence is emerging for the probable role of pro-
phylactic ischemic scar ablation to preventVT. Thismight increase the number of procedures performed. Herewe
look at the various complications of RF ablation and also themethods tominimize them. Electronic database was
searched for relevant articles from 1990 to 2015. With better awareness and technological advancements in RF
ablation the incidence of complications has improved considerably. In AF ablation it has decreased from 6% to
less than 4% comprising of vascular complications, cardiac tamponade, stroke, phrenic nerve injury, pulmonary
vein stenosis, atrio-esophageal ﬁstula (AEF) and death. Safety of SVT ablation has also improved with less than
1% incidence of AV node injury in AVNRT ablation. In VT ablation the incidence of major complications was
5–11%, up to 3.4%, up to 1.8% and 4.1–8.8% in patients with structural heart disease, without structural heart dis-
ease, prophylactic ablations and epicardial ablations respectively. Vascular and pericardial complications domi-
nated endocardial and epicardial VT ablations respectively. Up to 3% mortality and similar rates of tamponade
were reported in endocardial VT ablation. Recent reports about the high incidence of asymptomatic cerebral em-
bolism during AF ablation are concerning, warranting more research into its etiology and prevention.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
RF ablation has been part of clinical practice for more than two de-
cades and has become an important treatment option for most clinically
relevant cardiac arrhythmias. Achieving the optimal balance between ef-
ﬁcacy and safety has proven to be challenging. Even though procedure-
related acute complications are on the decline by virtue of better knowl-
edge of arrhythmia physiology, experience of particular group with RF
ablation and advancements in technology like mapping, cryoablation
and newer ablation techniques such as magnetic navigation [1–3]. How-
ever the incidence of some chronic complications has risen, as procedures
became more complex and time consuming.
Catheter ablation procedures are used to treat a diverse range of
arrhythmiaswith vastly different natural histories and alternative treat-
ment options. For the purposes of this review we will consider three
broad types of procedures. Pulmonary vein isolation (PVI) for AF abla-
tion for SVT and VT ablation.
Electronic database was searched for relevant articles from 1990
to 2015. Search terms namely radiofrequency ablation, safety,estmead Hospital, Corner Darcy
skaran).
land Ltd. This is an open access articlcomplications, AF, atrio ventricular reentry tachycardia (AVRT),
atrio ventricular nodal reentry tachycardia (AVNRT), VT and atrial
ﬂutter (A Fl) were used separately and in combination. Out of 5390
articles obtained through this search, 315 journal articles pertaining
to safety issues of RF ablation were carefully studied for the review.
Prospective and retrospective designs, and review articles were includ-
ed. Animal studies, in vitro studies, conference proceedings, case reports,
comments, and surgical ablation articles were excluded.
2. Atrial ﬁbrillation ablation
The technique of catheter ablation for atrial ﬁbrillation has developed
over a relatively short period of time. The incidence of major compli-
cations of AF ablation has decreased overtime. Studies from 1995 to
2010 show a reduction in serious complications from 6% to 3.7% of
which vascular complications were the commonest [4,35].
2.1. Cerebrovascular accident
The reported incidence of clinical stroke in AF ablation is much less
than 1% [5,6]. However, there is ample evidence to suggest that the sub-
clinical cerebral embolism during left sided ablations especially pulmo-
nary venous isolation (PVI) for AF is far more common. Asymptomatice under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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higher incidence of 41% was reported by the MACAP study when more
sensitive 3 Tesla MRI imaging was performed [8].
Medi et al. found 13–20% prevalence of cognitive dysfunction at
three months in AF patients treated with ablation compared to none
in those managed medically [9]. The presence of spontaneous echo
contrast and procedural duration before heparin administration were
determinants of ACL [10]. Therapeutic periprocedural anticoagulation
signiﬁcantly reduced ACL [11].
The possible embolic sources are thrombus formation on the abla-
tion electrode and sheath, debris from steam popping and charring,
preexisting thrombus in the cardiac chamber, air embolus from within
the sheath and fresh thrombus formed on damaged endothelial surface
of endocardial lesions [5,12,13].
Factors which have been proven to increase embolic risk are in-
creased catheter time in the left atrium (LA), chronicity of AF, activated
clotting time (ACT) below 250 seconds, duration of individual ablations,
larger LA size, non-irrigated ablation and the presence of spontaneous
echo contrast [5,14]. Periprocedural cardioversion was associated with
an increased incidence of embolic stroke in some studies, however
this association was not consistent [15,5,7].
Various methods have been used to minimize this embolic com-
plication, however none in isolation or in combination could
completely eliminate the risk of cerebral embolization. Intracardiac
thrombus causing embolism could be minimized by adequate
periprocedural anticoagulation. Several studies have shown the ideal
anticoagulation level to be 300–400 s of ACT [5,13]. Verma et al. success-
fully reduced silent embolism by submerged introduction of the catheter
into its sheath to prevent air entry [13]. Using intracardiac echocardiog-
raphy (ICE) Ren et al. demonstrated that thrombi mostly formed in the
sheath or mapping catheter and could be managed by withdrawing the
sheath and catheter from the LA [14]. Periprocedural continuation of
Warfarin reduced the incidence of stroke signiﬁcantly, without increas-
ing major bleeding or tamponade in Kuwahara et al.'s study of 3280 AF
ablation cases [16].
2.2. Esophageal tissue injury (ETI)
While esophageal injury appears to be common after AF ablation, the
incidence of atrio-esophageal ﬁstula (AEF), which is often fatal was rare
at 0.05% [17]. The incidence of esophageal injury deﬁned as erythema,
hematoma or ulcer was 2.9%–47% [18–21]. Schmidt et al. reported the
highest incidence of injury without ﬁstula formation in 47% using the
higher temperature, power and time limits of 50 °C, 50 W and
15 seconds of irrigated ablation [21]. The esophagus is often located less
than 5 mm from the LA posterior wall and thermally mediated injury
occurs due to direct heat transfer [97].
AEF typically occurs subacutely and up to 23 rd day post ablation has
been reported [22]. Clinical features are caused by air embolism (stroke)
and sepsis, which is associated with high mortality, greater than 80%
[23]. The initial symptoms may be subtle and a high index of suspicion
is required.
In one study, ETI was successfully averted by limiting esophageal
endoluminal temperature rise to 41 °C [19], however this was not a con-
sistent ﬁnding. Di Base et al. encountered 17% ETI even when ablation
was discontinued at 39 °C of endoluminal temperature [24]. Endoluminal
temperature underestimated esophageal tissue temperature by up to
20 °C and it peaked only 25 seconds after esophageal tissue temperature
peak in a canine study [25]. Good et al. explained the discrepancy ob-
served in endoluminal temperature by demonstrating more than 2 cm
sideways movement of esophagus during conscious sedation, which
could move the probe away from the ablation catheter [98].
Various factors such as the energy delivered to the LA posterior wall,
LA dilatation, additional ablation lines, LA size, LA-esophageal distance,
use of nasogastric tube in general anesthesia, low BMI and chronicity of
AF had been identiﬁed as predictors of ETI complications [18,20,26].Strategies used to prevent esophageal injury were reducing power to
25 W, reducing ablation duration to 30 seconds in the posterior wall
and ICE guidance to restrict microbubble formation. Martinek et al.
showed that esophageal visualizationwith barium contrast and limiting
energy delivery to 15Wwas effective in reducing ETI compared to lim-
iting duration of ablation to 5 seconds without reducing power and
without esophageal temperature monitoring [18]. None of these
methods were successful in completely eliminating ETI [18,21].
2.3. Left atrial tachycardia
LA tachycardia especially atrial ﬂutter which is usually incessant and
poorly tolerated is a common complication of AF ablation [34]. The inci-
dence could be as high as 29% [27,28]. It wasmore common in circumfer-
ential ablation compared to segmental isolation and also with additional
ablation lines [29,30]. The commonmechanismwasmacroreentry,which
was attributed to non-transmural or non-durable lesions and non-
contiguous ablation lines leading to reconnections across gaps [31]. The
risk was lessened if bidirectional block was demonstrated after ablation.
Half of atrial tachycardia cases persisted three months post-ablation
warranting repeat ablation [32]. Cummings et al. demonstrated that the
treatment need not be linear ablation and often disconnection of the
electrically reconnected pulmonary vein was effective [33]. Mitral
annular reentry was a common cause of atrial ﬂutter after single ring or
box isolation ablation for AF [34].
2.4. Pulmonary vein stenosis
Pulmonary vein stenosis (PVS) is deﬁned as 50% or more narrowing
of the venous lumen, andmore than 70% stenosis is termed severe [23].
In 2002, Arentz et al. showed28% incidence of PVS,which in later studies
declined to 0.1–1.3% [22,35,36] and only 0.29% needed intervention [37].
This decreasing incidence was due to changing ablation site from pulmo-
nary vein lumen to antrum, reducing power of ablation and adopting ad-
ditional imagingmodalities to better delineate the ostial anatomy [38,39].
Dong et al. showed that encircling individual veins carriedmore risk com-
pared to encircling ipsilateral pairs [40].
Patientswith exertional dyspnea,which is the commonest symptom
usually have stenosis exceeding 70% in multiple veins [39]. CT scan is
widely used to diagnose PVS. Holmes et al. identiﬁed a small lumen by
pulmonary angiography in 50% of patients whom CT scan showed
complete occlusion. This ﬁnding has treatment implications as total
occlusion is not amenable to stenting [39]. MR imaging was also
equally useful as CT scanning [23]. Functional assessment with V/Q
scan helped in identifying asymptomatic patients with severe stenosis
[38,39]. Progression of stenosis was variable. Saad et al. reported 8.8%
progression mainly in ﬁrst 3 months and regression in 10.4% [38].
Most clinicians perform stenting for residual stenosis after balloon
angioplasty, whereas some prefer primary stenting [36,39]. Even
though angioplasty and stenting reduced the incidence of restenosis in
patients with symptomatic severe stenosis compared to balloon dilata-
tion alone, the restenosis rates remained high at 30–50% [36,38,39].
Some clinicians prefer to intervene in severe stenosis irrespective of
symptoms because progression to complete occlusion could be rapid
which might preclude intervention [38,39].
2.5. Phrenic nerve injury
Phrenic nerve injury (PNI) has a prevalence of 0.1–0.5% after AF abla-
tion [41]. Right PNI is often associated with ablation of the anteroinferior
aspect of the right superior pulmonary vein (RSPV) or posteroseptal
portion of superior venacava, owing to their close proximity to the
nerve [42,48]. Although less common, left PNI was reported in AF
ablation resulting from application of RF energy close to the proximal
LA appendage roof [43].
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AF ablation, dyspnea is a cardinal symptom and is present in all symp-
tomatic patients [43]. Other symptoms include cough and hiccough
and the diagnosis ismade by the demonstration of diaphragmatic eleva-
tion on chest radiograph [43]. In a study by Sacher et al., 66% of patients
recovered completely at 36 ± 33 months after ablation, 17% partially
recovered and 17% failed to recover [43]. Avoiding PNI may be possible
by using high output “pace mapping” in high risk areas before ablation
[43].
2.6. Perforation and tamponade
AF ablation carriesmore risk of perforation up to 2.4% compared to VT
and SVT ablations [35,44,45], probably due to the longer catheter manip-
ulation time, higher number of ablations and higher anticoagulation [46].
Using ICE for transeptal puncture and reducing the temperature limit of
irrigated ablations to 42 °C had been recommended [6]. A 1.2% incidence
of delayed tamponade was reported by Cappato et al. with an average
presentation of 12 days post-ablation [47].
Majority of patients respondedwith pericardiocentesis and very few
required surgical closures. Maximal power delivery in excess of 48 W
was a signiﬁcant risk factor for developing cardiac tamponade during
atrial ablations and limiting power delivery to less than 42 W reduced
the incidence of perforations [45]. The use of ICE in some studies facili-
tated early detection of effusion before overt hemodynamic instability
[6,44].
2.7. Death
The leading causes of death of 0.15% in the world-wide survey were
cardiac tamponade, stroke and atrio esophageal ﬁstula. 22% of deaths
occurred after a month, attributed to various causes namely, hematoma
causing tracheal compression, intracranial bleeding and esophageal
perforation from pre-procedural trans-esophageal echocardiogram use
[23].
2.8. Radiation exposure
Catheter ablations for AF may require prolonged ﬂuoroscopy times.
Pre-procedural CT scanning for anatomical mapping may further in-
crease the radiation burden. Prolonged radiation exposure during the
procedure puts the patient and also the operator at risk of malignancy
and genetic abnormalities. Fluoroscopy time for ablation of persistent
AFwas reported to be 80–100min [49]. Sixtyminutes of radiation expo-
sure translates to 0.03% increased life time risk for fatal malignancies
whichwas higher for obese patients [50]. Newer technologies for naviga-
tion such as magnetic navigation and 4D non-ﬂuoroscopic ablation were
shown to be effective in reducing ﬂuoroscopy time [1,51].
2.9. Miscellaneous complications
Mitral valve injury during AF ablation by trapped circular catheter is
a rare complication. Surgical extraction is often required to prevent
injury to valve apparatus if gentle manipulation fails [23].
Perioesophageal vagal nerve injury usually presents with upper gas-
trointestinal symptoms following AF ablation and the incidence could
be as high as 1%. Abnormal gastric motility and pyloric spasm is usually
treated symptomatically however, severe cases need botulinum injec-
tion, surgery or gastric pacing. Prevention is similar to that for esophageal
tissue injury [99].
Atrial size and contractility improved after most AF ablations sug-
gesting a positive remodeling effect of the intervention. Loss of con-
tractility was proportional to the amount of myocardium damaged as
circumferential ablations resulted in more loss of atrial function com-
pared to segmental ablation [32].Vascular access complications have shown a favorable trend after
the practice of ablationwith uninterrupted warfarin had started, proba-
bly due to lesser use of bridging Enoxaparin. However, they are still the
commonest [23] (Table 1).
2.10. Summary
With better awareness and technological advancements in RF abla-
tion, the incidence of complications has improved considerably. In AF ab-
lation it has decreased from 6% to less than 4% comprising of vascular
complications, cardiac tamponade, stroke, PNI, PVS, AEF and death. ACL
is a potentially signiﬁcant issue with possible long-term consequences.
Continuing warfarin and strict intra-procedural anticoagulation reduced
its incidence. AEF is often a fatal complication, which could be prevented
to an extent with esophageal temperature monitoring. Atrial tachycardia
post-AF ablation, which is often very symptomatic, is a common compli-
cation and the incidence was reduced by demonstrating bidirectional
block. Pulmonary vein stenosis is on the decline after circumferential
PVI was adopted. Presenting symptom could be only dyspnea and high
index of suspicion is required to diagnose. PNI could be prevented by
high output pacing in high- risk areas before ablation. Reducing target
temperature and also the delivered power reduced the incidence of peri-
cardial tamponade. ICE guidance for transeptal puncture and pericardial
monitoring also helped to reduce morbidity with this complication.
Vascular access site complications were the commonest, which showed
a favorable trend after performing procedure on warfarin.
3. Supraventricular tachycardia ablation
3.1. AV node injury
AV nodal (AVN) injury is predominantly a complication of AVNRT
ablation. The incidence had been high initially at 5.6% in the MERF
studywhen the fast pathwaywas targeted by virtue of its close proximity
to the compact AV node [52].With change in the ablation site to the slow
pathway's posteroinferior location which is further away from the AV
node, the incidence decreased to 0.07%–0.7% [53,54,55].
Ablations for aortic cusp SVT, accessory pathways and outﬂow tract
VTwere also associatedwith this complication [56]. In a 14 year study of
5330 consecutive SVT ablation cases of AVNRT, AVRT, A Fl and AT by
O'Hara et al., permanent AVBwas observed in 0.22% of AVNRT ablations
and 0.17% of AVRT ablations [57]. French registry reported 0.1% and 1.5%
incidence of AV nodal injury in AVRT and AVNRT ablations respectively
[58].
3.2. Mortality
Calkins et al.'s prospective study of SVT ablations (1999) reported
0.1% mortality in AVRT ablations and none in AVNRT ablations [59].
Feldman et al. did not report any death in 1448 AVNRT ablations [53].
However, 0.04%mortality was reported in 1996 from the French registry
of more than 5000 predominantly SVT cases [58].
3.3. Miscellaneous complications
Perforation occurred in 0.1–1.3% [60] (Table 2). Complications could
occur during atrial ﬂutter ablation as well which was shown by
Brembilla-Perrot et al. where they have reported up to 1.6% chance of
life threatening complications when an 8 mm tip catheter was used
with setting of 70 W, 70 °C, for 60 seconds [61].
3.4. Summary
AV nodal injury is themost concerning complication of SVT ablation
especially AVNRT and septal accessory pathways. Adoption of slow
pathway ablation for AVNRT reduced the incidence to well below 1%.
Table 1
Complications of atrial ﬁbrillation ablation.
Study Type Year Procedure
(n)
Major
complications
Death CVA Tamponade PVS AEF PNI Vascular
Worldwide survey [35] Multicenter survey 1995–2002 11,672 6 0.05 0.94 1.22 1.31 (chronic) 0.42 0.74 1
Updated world-wide survey [37] Multicenter survey 2003–2006 20,825 4.5 0.15 0.94 1.31 0.29 (intervention) 0.04 0.17 1.5
Baman et al. [96] Prospective 2007–2010 1295 3.5 0 0.5 1.2 – 0 0 1.9
Bertaglia et al. [95] Retrospective 2011 2323 4 0 0.3 0.5 – – 0.1 2.2
Stabile et al. [4] Prospective 2011 2167 3.7 0 0.3 0.6 – – 0.1 2.1
AEF—atrio-esophageal ﬁstula.
CVA—cerebrovascular accident (including transient ischemic attack).
PNI—phrenic nerve injury (needing intervention).
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The incidence of major complications of VT ablation was reported to
be 5–11%, up to 3.4% and up to 1.8% in patients with structural heart
disease, without structural heart disease and prophylactic ablations re-
spectively [2,46,62–65]. Prophylactic, scar VT ablations are those under-
taken after the ﬁrst arrhythmia as opposed to ablation after recurrent
ventricular arrhythmias [63,64]. Up to 8.5% major complication rate
was reported in epicardial ablations [66,67].
In Peichl et al.'s study of 722 patients, advanced age, LV dysfunction,
renal failure and the proceduralist experience were identiﬁed as the
predictors of complications [62]. Renal function was the only predictor
of complications in VT ablation identiﬁed in Bohnen et al.'s study [46].
Neither advanced age nor LV dysfunction was a predictor of complica-
tions. Age more than 75 years was not a predictor in Inada et al.'s
study either [68].4.1. Death
The combined mortality in ischemic and non-ischemic VT ablations
ranged from 0 to 3% [46,68–72], which was frequently due to fast VT
leading to cardiogenic shock [68,71,73]. Incomplete procedural success
was a predictor of in-hospital mortality [72].4.2. Perforation and tamponade
The incidence of cardiac perforation ranged from 1 to 2.7% [74,75].
Tokuda et al. reported 1% incidence of cardiac perforation during VT
ablation in the largest single center study [74]. More than half of these
patients with cardiac perforations required surgical repair if preceded
by steampop andmost perforations occurred during thin-walled RV ab-
lation, in particular the outﬂow tract.
During epicardial ablation, tamponade was the commonest major
complication [67,76], constituting 5.1% out of 7% major complicationsTable 2
Complications of supra ventricular tachycardia ablation.
Study Type Year Procedure (n) SVT
MERFS [52] Prospective 1987–1992 880 AVN
Feldman et al. [53] Retrospective 1999–2009 1419 AVN
O'Hara et al. [57] Prospective 1993–2006 5330 AVN
AVR
AT
A Fl
AP—accessory pathway, AVNRT—AV nodal reentrant tachycardia.
A Fl—atrial ﬂutter.
a High grade requiring pacemaker implantation.
b Stroke and TIA.in a study [67]. Inadvertent RV puncture occurred in 20% of cases during
epicardial access without any adverse consequence.4.3. Coronary artery injury
Coronary artery injury is an uncommon complication of RFA with
reported incidence of 0.09% of all ablations [77], and 1.5% of epicardial
ablations [67]. Safe distance of ablation from a coronary artery had
been suggested from 2 mm to 12 mm by different authors [78,79,80].
Themanifestations of coronary injury could be acute, delayed or chronic
[67,77,81]. Acute effects included vasospasm, intimal damage and
thrombus formation [78,82]. Chronic effects were ﬁbrosis and thickening
of all three layers of the artery [81]. The artery damagewas inversely pro-
portional to vessel size [83].
This complication could occur during both endocardial and epicardial
ablations performed in close proximity to the coronary arteries. High-risk
areas are the posteroseptal region, sub-eustachian isthmus and coronary
sinus and its branches. Injury had also been reported following ablations
for typical atrial ﬂutter, AVNRT, AVRT and coronary sinus ablations [84].
Acute coronary occlusion warrants angioplasty and stenting [77].
Coronary angiography before energy delivery in the epicardium could
help in preventing coronary injury [67].4.4. Miscellaneous complications
Vascular complications were the commonest in VT ablation, which
was reported up to 4.7%. The incidence of CVA ranged from 0% to 1.4%
[68–71], while high grade AV block occurred in up to 1.8% [72,68,70].
The use of ICE was found to be useful in early detection of complica-
tions and visualization of great arteries and coronaries in outﬂow tract
ablations [3] High output pacing before ablation near the lateral wall
of LV should be considered to avoid phrenic nerve injury in epicardial
ablations [76]. A dedicated VT ablation multidisciplinary intensive care
team, complete with support staff as shown by Della Bella et al. hastype (%) AV blocka (%) CVAb (%) Tamponade (%) Death (%)
RT 5.6 – – –
RT 0.07 – – –
RT 0.22 0 0 0
T 0.17 0 0.09 0
0 0 0 0
0 0 0 0
Table 3
Complications of ventricular tachycardia ablation.
Study Type Year Proc (n) VT type Major complications Death CVA Tamponade Other
Structural heart disease
Sauer et al. [69] Prospective 1999–2005 327 ICM, NICM 2.1% Nil 0.9% 1.2 –
Euro VT [94] Prospective 1999–2003 63 ICM 1.5% 0 0 0
Bohnen et al. [46] Prospective 2009–2011 250 SHD 6% 0.4% 0.8% 1.4%
Mallidi et al. [70] Meta-analysis 1965–2010 457 SHD 6.3% 1% 1% – AV blocka 1.6%
Perforation 1%
Tokuda et al. [74] Prospective 1999–2010 226 NICM 5% 0 0 0 Perforation 1.8%
Dinov et al. help-VT study [65] Prospective 2008–2011 227 ICM, DCM 11% 0.4% – 0.8% AV block 0.8%
Shock 2.2%
Peichl et al. [62] Prospective 2006–2012 473 8% 0 0.8% 0.6% AV block 1.3%
Vascular 4.7%
Della Bella et al. [2] Prospective 2007–2012 634 SHD 7% 0.1% 0 2% Vascular 4%
Idiopathic
Inada et al. [68] Prospective 1999–2008 285 IVT 7% 3.8% 0.7% 0.7% AV block 1%
Bohnen et al. [46] Prospective 2009–2011 119 IVT 3.4% 0 0.8% 0.8%
Peichl et al. [62] Prospective 2006–2012 249 IVT 2.8% 0 0.4% 0 AV block 0.4%
Vascular 1.6%
Prophylactic
SMASH VT [64] RCT 2004–2006 64 ICM 0 0 0 0 1 DVT, 1 CCF
VTACH [63] RCT 2002–2006 54 ICM 1.8% 0 1.8% – 1 ST elevation
Epicardial
Della Bella et al. [76] Multicenter Survey 2001–2009 218 SHD, NSHD 4.1% 0 0 3.7% 1 abdominal hemorrhage
Sacher et al. [67] Multicenter Survey 2001–2007 136 SHD 7% 0 0 5.1% CA stenosis 0.6%
Tung et al. [66] Single center Survey 2004–2011 109 SHD, NSHD 8.8% 0 0 0 6.7% epicardial bleeding
RCT— randomized controlled trial.
CVA—cerebrovascular accident (including transient ischemic attack).
IVT- Idiopathic Ventricular Tachycardia
SHD- Structural Heart Disease
NSHD- No Structural Heart Disease
ICM- Ischemic Cardiomyopathy
NICM- Non Ischemic Cardiomyopathy
a High grade requiring pacemaker implantation.
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major complications. (4% vascular complications) [2] (Table 3).
4.5. Summary
VT ablation suffered the highest incidence of complication among
RF ablations. The incidence of major complications was 5–11%, up to
3.4%, up to 1.8% and 4.1–8.8% in patients with structural heart disease,
without structural heart disease, prophylactic ablations and epicardial
ablations respectively. Vascular and pericardial complications dominat-
ed endocardial and epicardial VT ablations respectively. Coronary artery
injury wasmore common in epicardial ablation. Up to 3% mortality and
similar rates of tamponade were reported in endocardial VT ablation.
Dedicated VT multidisciplinary team and ICE guidance during proce-
dure helped to reduce morbidity.
The extremes of age need specialmention. In pediatric SVT ablations,
Lee et al. reported that the incidence of complications was similar to
that in adults [85]. The risk of AVN injurywas atmaximumwith anterior
and mid-septal pathways [86]. Death occurred in 0.14% ablations as
reported by Vitello et al. in their study of 5000 procedures [87]. Schaffer
et al. observed that it was related to the lower bodyweight, presence of
structural heart disease and left sided procedures [88]. Special care
needs to be taken to reduce radiation in pediatric population for obvious
reasons [89]. Tomaske et al. did not report any complications in 97 pedi-
atric SVT ablations [90].
The impact of advanced age on safety of RF ablations is less clear.
Earlier report by Chen et al. in 1996 in 3966 RF ablation procedures,
showed that elderly patients were at a higher risk for complications
[91]. Piechl et al. also recently reported that the complications in VT abla-
tion were associated with advanced age [62]. However, both Santangeli
et al. in AF ablation and Inada et al. in VT ablation did not report increased
complication in elderly [68,92].5. Newer technology
Magnetic Navigation System (MNS) is a new technological advance-
ment in radiofrequency ablation [93], in which two powerful magnets
are used to navigate the magnetic irrigated catheter precisely to the
destination. In one studyMNS ablations suffered only 0.34%major com-
plications when compared to 3.2% with conventional ablation in 610
consecutive patients with various arrhythmias [1].
Non-ﬂuoroscopic 4D ablation technology, popularly known as
MediGuide, uses pre acquired X-ray images to superimpose catheter po-
sition. This considerably reduces radiation exposure. Real time tracking
of catheter accounting for respiratory and cardiacmovements is another
advantage [51].
Conﬂict of interest
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